TACE-HAIC
18 abstracts
Abstract
PD-1 inhibitor (sintilimab) and lenvatinib plus TACE-HAIC as conversion therapy for initially unresectable HCC: A single-arm, phase 2 clinical trial (PLATIC).Org: Department of Liver Surgery,
Abstract
Transarterial chemoembolization (TACE) combined with donafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A real-world clinical study.Org: The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou JOYO Pharma, China National Biotec Group,
Abstract
Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, non-randomized, open-label, phase II cohort study.Org: State Key Laboratory of Complex Severe and Rare Diseases, Division of Pulmonary and Critical Care Medicine, State Key Laboratory of Severe and Rare Diseases,
Abstract
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,
Abstract
Efficacy and safety analysis of donafenib combined with transarterial chemoembolization in the treatment of unresectable hepatocellular carcinoma: A prospective, single-arm, single center, phase II clinical study.Org: Intervention Ward One,
Abstract
Lenvatinib (LEN) combined with tislelizumab (TIS) plus transcatheter arterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II clinical trial.Org: Guangxi Medical University Cancer Hospital, Nanning, China, China National Biotec Group, Nnanning,
Abstract
Efficacy and safety of donafenib combined with transcatheter arterial chemoembolization (TACE) and anti-PD1 antibody for the treatment of unresectable hepatocellular carcinoma (uHCC): A retrospective study.Org: Eastern Hepatobiliary Surgery Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Clinical efficacy and safety of immune checkpoint inhibitor in combination with regorafenib therapy as second⁃line regimen for patients with unresectable hepatocellular carcinoma.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, Shandong Cancer Hospital and Institute, Jinan, shandong, China, Shandong Cancer Hospital and Institute, Jinan, China,
Abstract
Efficacy and safety of regorafenib alone or in combinations in the second-line setting for advanced hepatocellular carcinoma: A multicenter real-world study.Org: Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Nantong University, Nantong, China, Liver Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, China, Oncology Department, Siyang Hospital, Suqian, China,
Abstract
Donafenib combined with anti-PD-1 antibody and transarterial chemoembolization (TACE) as first-line (1L) treatment for unresectable/advanced hepatocellular carcinoma (HCC).Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Department of Interventional Radiology, Zhongshan Hospital, Fudan University,
Abstract
Real-world (RW) treatment and surveillance patterns in patients with hepatocellular carcinoma (HCC) after resection (R) or ablation (A): Evidence from commercial and Medicare populations.Org: Genentech,
Abstract
Efficacy and safety of donafenib combined with transarterial chemoembolization (TACE) for treating intermediate/advanced-stage hepatocellular carcinoma (HCC): A retrospective real-world study.Org: University of Science and Technology of China,
Abstract
A retrospective study on the efficacy and safety of regorafenib alone or in combination in advanced hepatocellular carcinoma.Org: Department of Vascular Intervention, Nantong 3rd People's Hospital, Nantong, China, Department of Interventional & Vascular Surgery, Affiliated Hospital of Nantong University, Nantong, China, Department of Interventional Medicine, Nantong 3rd People's Hospital, Nantong, China,
Abstract
The efficacy and safety of donafenib-containing regimens as postoperative adjuvant therapy for hepatocellular carcinoma (HCC): A multicenter retrospective study.Org: Hepatobiliary Center of The First Affiliated Hospital Nanjing Medical University, Nanjing, Jiangsu, Nanjing, China, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Abstract
A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery.Org: Eastern Hepatobiliary Surgery Hospital, Shanghai, China,
Abstract
Anlotinib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma associated with hepatitis B virus: A retrospective controlled study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, Sun Yat-sen University State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine,
Abstract
Liver directed therapies in primary and metastatic liver cancer: A rural academic institution experience.Org: ECU Health/ Brody School of Medicine, East Carolina University Brody School of Medicine, Brody School of Medicine at East Carolina University,
Abstract
Efficacy and safety of transarterial chemoembolization in combination with lenvatinib and tislelizumab for patients with unresectable BCLC-B stage hepatocellular carcinoma classified as beyond up to seven criteria: A retrospective study.Org: Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center and Sun Yat-sen University State Key Laboratory of Oncology in South China, and Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,